Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Biogen partners with City Therapeutics to develop select novel RNAi-based therapies: Cambridge, Massachusetts Thursday, May 29, 2025, 10:00 Hrs [IST] Biogen Inc, a leading biotech ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Bicara Therapeutics presented data from an ongoing, 28-patient trial of its drug showing median overall survival of over 21 ...

Novartis launched a tender offer for Regulus Therapeutics. Biogen and City Therapeutics announced a partnership to develop a drug for an undisclosed central nervous system disease. Eli Lilly bought ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise ...